Summary of Study ST001925

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001215. The data can be accessed directly via it's Project DOI: 10.21228/M8NQ5X This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001925
Study TitleMS Untargeted Metabolomics from Human Serum
Study SummaryMultiple Myeloma patients were treated with the proteasome inhibitor carfilzomib in different protocols according to their clinical stage. Paired serum samples were obtained before i.v injection and after 1-8h post treatment and snap frozen. Samples were stored at -80°C until analysis.
Institute
University of Zurich
Last NameMendez
First NameMax
AddressRorschacherstrasse 95. 9007, St.Gallen
Emailmaxmendez@runbox.com
Phone+41 71 494 10 67
Submit Date2021-09-21
Num Groups2
Total Subjects6
Num Males5
Num Females1
Raw Data AvailableYes
Raw Data File Type(s)raw(Waters)
Analysis Type DetailLC-MS
Release Date2022-01-02
Release Version1
Max Mendez Max Mendez
https://dx.doi.org/10.21228/M8NQ5X
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001215
Project DOI:doi: 10.21228/M8NQ5X
Project Title:Metabolic Changes in Multiple Myeloma Patients after CFZ treatment
Project Type:MS Untargeted Metabolomics from Human Serum
Project Summary:In this study we aimed to examine the acute metabolomic changes following proteasome inhibition with Carfilzomib within 8h of treatment.
Institute:University of Zurich
Department:Department of Hematology-Oncology. Kantonsspital St. Gallen
Laboratory:Experimental Hematolgy-KSSG
Last Name:Mendez
First Name:Max
Address:Rorschacherstrasse 95, 9007, St. Gallen.
Email:maxmendez@runbox.com
Phone:+41 71 494 10 67

Subject:

Subject ID:SU002003
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:49-79 years old
Gender:Male and female
Human Medications:All patients had received at lest 3 lines of anti-myeloma therapy
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id class
SA178102Post1_NEGPOSTREATMENT
SA178103Post1_POSPOSTREATMENT
SA178104Post5_NEGPOSTREATMENT
SA178105Post6_POSPOSTREATMENT
SA178106Post3_NEGPOSTREATMENT
SA178107Post3_POSPOSTREATMENT
SA178108Post5_POSPOSTREATMENT
SA178109Post6_NEGPOSTREATMENT
SA178110Post2_POSPOSTREATMENT
SA178111Post4_POSPOSTREATMENT
SA178112Post2_NEGPOSTREATMENT
SA178113Post4_NEGPOSTREATMENT
SA178114Pre4_POSPRETREATMENT
SA178115Pre5_POSPRETREATMENT
SA178116Pre1_POSPRETREATMENT
SA178117Pre2_POSPRETREATMENT
SA178118Pre3_POSPRETREATMENT
SA178119Pre6_POSPRETREATMENT
SA178120Pre2_NEGPRETREATMENT
SA178121Pre1_NEGPRETREATMENT
SA178122Pre6_NEGPRETREATMENT
SA178123Pre3_NEGPRETREATMENT
SA178124Pre4_NEGPRETREATMENT
SA178125Pre5_NEGPRETREATMENT
SA178126QC_14_POSQC
SA178127QC_13_POSQC
SA178128QC_11_POSQC
SA178129QC_12_POSQC
SA178130QC_06_POSQC
SA178131QC_10_NEGQC
SA178132QC_11_NEGQC
SA178133QC_09_NEGQC
SA178134QC_08_NEGQC
SA178135QC_07_NEGQC
SA178136QC_12_NEGQC
SA178137QC_13_NEGQC
SA178138QC_08_POSQC
SA178139QC_09_POSQC
SA178140QC_07_POSQC
SA178141QC_06_NEGQC
SA178142QC_14_NEGQC
SA178143QC_10_POSQC
Showing results 1 to 42 of 42

Collection:

Collection ID:CO001996
Collection Summary:Anesthesia was induced with Ketamine 80 mg/kg intramuscular and maintained with Isoflurane 0.5%. Plasma was obtained by centrifugation after cervical dislocation under anesthesia. Samples were snap frozen in dry ice and kept at -80°C until analysis.
Sample Type:Blood (plasma)
Storage Conditions:Described in summary

Treatment:

Treatment ID:TR002015
Treatment Summary:See attached file
Treatment Compound:Carfilzomib i.v
Treatment Route:i.v
Treatment Dose:As described in attached file

Sample Preparation:

Sampleprep ID:SP002009
Sampleprep Summary:No. Step 1 Take 40 μL of each sample into the 96-well plate; 2 Insert fetal bovine serum (more than 50, insert one for every 10 samples; 50 or less are not considered); 3 Add 120 μL of pre-cooled methanol, mix and shake for 1 min, and place in a refrigerator at -20°C for 2h or overnight; 4 4,000g * 4°C centrifugation for 30 min; 5 Place 25 μL of each sample in a new 96-well plate and dilute with 225 μL of 50% methanol; 6 Take 50 μL of each sample and mix to QC sample; 7 Take 60 μL of the supernatant and transfer to a 96-well microplate, seal the membrane and test it on the machine.
Processing Storage Conditions:-80℃
Extract Storage:-80℃

Combined analysis:

Analysis ID AN003128 AN003129
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Waters Acquity Waters Acquity
Column Waters Acquity BEH HSS T3 (100 x 2.1mm,1.8um) Waters Acquity BEH HSS T3 (100 x 2.1mm,1.8um)
MS Type ESI ESI
MS instrument type Triple quadrupole Triple quadrupole
MS instrument name Waters Xevo-TQ Waters Xevo-TQ
Ion Mode NEGATIVE POSITIVE
Units m/z m/z

Chromatography:

Chromatography ID:CH002311
Chromatography Summary:All samples were acquired by the LC-MS system followed machine orders. Firstly, all chromatographic separations were performed using an ultra performance liquid chromatography (UPLC) system (Waters, UK). An ACQUITY UPLC HSS T3 column (100 mm*2.1 mm, 1.8 μm, Waters, UK) was used for the reversed phase separation. The column oven was maintained at 50 °C. The flow rate was 0.4 ml/min and the mobile phase consisted of solvent A (water + 0.1% formic acid) and solvent B (methanol + 0.1% formic acid). Gradient elution conditions were set as follows: 0~2 min, 100% phase A; 2~11 min, 0% to 100% B; 11~13 min, 100% B; 13~15 min, 0% to 100% A. The injection volume for each sample was 5 µL.
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH HSS T3 (100 x 2.1mm,1.8um)
Flow Gradient:0.4 ml/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% methanol; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS002908
Analysis ID:AN003128
Instrument Name:Waters Xevo-TQ
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:he additive ions when the substance is ionized at the ion source are negative ions such as COOH-, OH-. , the capillary and sampling cone voltages were set at 2.0 kV and 40.0 V, respectively.
Ion Mode:NEGATIVE
  
MS ID:MS002909
Analysis ID:AN003129
Instrument Name:Waters Xevo-TQ
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:The additive ions when the substance is ionized at the ion source are positive ions such as H+, NH4+, K+. , the capillary and sampling cone voltages were set at 3.0 kV and 40.0 V, respectively
Ion Mode:POSITIVE
  logo